WO2010058512A1 - Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives - Google Patents

Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives Download PDF

Info

Publication number
WO2010058512A1
WO2010058512A1 PCT/JP2009/004975 JP2009004975W WO2010058512A1 WO 2010058512 A1 WO2010058512 A1 WO 2010058512A1 JP 2009004975 W JP2009004975 W JP 2009004975W WO 2010058512 A1 WO2010058512 A1 WO 2010058512A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzo
imidazole
hydroxy
carboxamide
thiophen
Prior art date
Application number
PCT/JP2009/004975
Other languages
English (en)
French (fr)
Inventor
Yo Matsuo
Ryuji Ohsawa
Shoji Hisada
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0920959A priority Critical patent/BRPI0920959A2/pt
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Priority to CN2009801549899A priority patent/CN102292083A/zh
Priority to RU2011124960/04A priority patent/RU2011124960A/ru
Priority to US13/129,361 priority patent/US20110301146A1/en
Priority to JP2011522179A priority patent/JP2012509249A/ja
Priority to CA2744012A priority patent/CA2744012A1/en
Priority to MX2011005369A priority patent/MX2011005369A/es
Priority to SG2011036282A priority patent/SG171761A1/en
Priority to AU2009318719A priority patent/AU2009318719A1/en
Priority to EP09827294A priority patent/EP2358365A4/en
Publication of WO2010058512A1 publication Critical patent/WO2010058512A1/en
Priority to IL212704A priority patent/IL212704A0/en
Priority to ZA2011/04487A priority patent/ZA201104487B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to a compound for inhibiting GSK-3beta activity, a method for the preparation thereof, and a pharmaceutical composition containing the compound as an active ingredient.
  • Glycogen synthase kinase-3 (GSK-3) is a proline-directed serine-threonine kinase that was initially identified as a protein which inactivates glycogen synthase through phosphorylation. Two isoforms have been identified, alpha (GSK-3alpha) and beta (GSK-3beta), which show a high degree of amino acid homology to each other. Previous studies have reported that the GSK-3beta is involved in energy metabolism, neural cell development, and body pattern formation (NPL 1).
  • Neurodegenerative naturopathies including Alzheimer disease, are characterized by abnormal hyperphosphorylation of the microtubule-associated protein tau at proline- directed serine/threonine phosphorylation sites (NPL X).
  • NPL X proline- directed serine/threonine phosphorylation sites
  • GSK-3beta has been identified as a prime candidate mediating aberrant tau phosphorylation at disease- associated sites (NPLs 3-6).
  • NPLs 3-6 disease- associated sites
  • GSK-3beta is a promising target for therapeutic intervention in neurodegenerative tauopathies including Alzheimer disease.
  • Lithium carbonate, lithium citrate and lithium chloride are commonly used for the treatment of various disorders like mania, depression and migraine, and also used as an "augmenting" agent to increase the benefits of other standard drugs used for unipolar depression.
  • Lithium is a GSK-3beta inhibitor, and therefore, GSK-3beta inhibition is a promising target for the treatment of various such disorders.
  • GSK-3 inhibitors are available for treatment of type 2 diabetes by reducing the activity of glucose synthase.
  • GSK-3beta inhibitors can be used for a broad spectrum of diseases such as Alzheimer disease, mania, depression, migraine and type 2 diabetes and there is a strong need to develop such inhibitors for the treatment and/or prevention of GSK-
  • the present inventors have endeavored to develop an effective inhibitor of GSK-3beta and have found that a benzoimidazole derivative can selectively inhibit the activity of
  • NPL 1 Plyte SE, et al., Biochim. Biophys. Acta, 1114:147-162, 1992
  • NPL 2 Lee VM, et al., Annu. Rev. Neurosci. 24: 1121-1159, 2001
  • NPL 3 Hanger DP, et al., Neurosci. Lett. 147: 58-62, 1992
  • NPL 4 Ishiguro K, et al., J. Biol. Chem. 267: 10897-10901, 1992
  • NPL 5 Mandelkow EM, et al., FEBS Lett. 314: 315-321, 1992
  • NPL 6 Paudel HK, et al., J. Biol.
  • a GSK-3beta inhibitor having high inhibitory activity against GSK-3beta. It is a further object of the present invention to provide a pharmaceutical composition including the compound, a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof for use in the treatment of GSK-3beta dependent diseases in a patient in need thereof.
  • a compound of formula (I) and a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof:
  • X is phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, cyclopentyl, phenylCi-C 6 alkyl, thiophen-2-ylCi-C 6 alkyl, furan-2-ylCi-C 6 alkyl, cyclopropylCi-C 6 alkyl, or cy- clopentylCi-C 6 alkyl; the said phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, cyclopentyl, phenylQ -C 6 alkyl, thiophen-2-ylCi-C 6 alkyl, furan-2-ylCi-C 6 alkyl, cyclopropylCi-C 6 alkyl, or cyclopentyl Ci-C 6 alkyl are optionally substituted by 1-3 substituent(s) each independently selected from the group A; L is -
  • M is selected from C 3 -C 8 cycloalkyl or 3-8 membered saturated heterocyclic group; the C 3 -C 8 cycloalkyl, and 3-8 membered saturated heterocyclic group are optionally substituted by 1-3 substituent(s) each independently selected from group A; wherein group A consists of hydroxyl, oxo, nitro, cyano, amino, Ci-C 6 alky lamino, C 3 - C 8 cycloalkylamino, amide, halogen, sulfamoyl, trifluolomethyl, p- toluenesulfonylamino, Ci-C 6 alkyl, C 3 -C 8 cycloalkyl, Ci-C 6 alkoxy, Ci-C 6 alkylcar- bonylamino, Ci-C 6 alkylsulfonyl, Ci-C 6 alkylsulfonylamino, Ci-C 6 alkenyl, Ci-C 6 alkyny
  • a “GSK-3beta dependent disease” is a disease in which inhibiting GSK-3beta activity is relevant to therapeutic efficacy.
  • diseases include, for example, Alzheimer disease, mania, depression, migraine and type 2 diabetes. It will be understood by one of skill that such diseases do not include cancers, such as breast cancer, bladder cancer and small cell lung cancer.
  • the claimed methods of treating or preventing a GSK-3beta dependent disease exclude patients also suffering from cancer, such as breast cancer, bladder cancer or small cell lung cancer.
  • a patient in need thereof refers to a patient suffering from a GSK-3beta dependent disease, with the proviso that the patient is not also suffering from cancer, such as breast cancer, bladder cancer or small cell lung cancer.
  • alkyl refers to a straight chain or a branched chain hydrocarbon group which does not contain any hetero atoms or unsaturated carbon-carbon bonds.
  • Ci-C 6 alkyl refers to an alkyl group which has 1-6 carbon atom(s).
  • Ci-C 4 alkyl refers to an alkyl group which has 1-4 carbon atom(s).
  • Ci-C 6 alkyl examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 2-methyl-l -propyl, 2-methyl-2-propyl, 1 -butyl, 2-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-l -butyl, 3-methyl-l -butyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 2,2-dimethyl- 1 -propyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-l-pentyl, 3-methyl-l-pentyl, 4-methyl-l-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2-methyl-3-pentyl, 3-methyl-3-pentyl, 2,3-dimethyl-l -butyl, 3,3-dimethyl-l-but
  • phenylCi-C 6 alkyl, thiophen-2-ylCi-C 6 alkyl, furan-2-ylCi-C 6 alkyl, cyclopropylCi-C 6 alkyl, or cyclopentylCi-C 6 alkyl refers to the Ci-C 6 alkyl bound to a phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl or cyclopentyl group.
  • phenylCi-C 6 alkyl, thiophen-2-ylCi-C 6 alkyl, furan-2-ylCi-C 6 alkyl, cy- clopropylCi-C 6 alkyl, or cyclopentylCi-C 6 alkyl is optionally substituted by 1-3 sub- stituent(s) each independently selected from group A mentioned above. Such substitution may occur at either the phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, or cyclopentyl moiety or the Ci-C 6 alkyl moiety of the group, or may occur at both moieties of the group.
  • phenylCi-C 6 alkyl, thiophen-2-ylCi -C 6 alkyl, furan-2-ylCi -C 6 alkyl, cy- clopropylCi -C 6 alkyl, or cyclopentylCi-C 6 alkyl include, but are not limited to, phenylmethyl, phenylethyl, phenyl- 1 -propyl, phenyl-2-propyl, phenyl-n-butyl, phenyl- s-butyl, phenyl-t-butyl, phenyl-2-ethylbutyl, thiophen-2-ylmethyl, thiophen-2-ylethyl, thiophen-2-yl- 1 -propyl, thiophen-2-yl-2-propyl, thiophen-2-yl-n-butyl, thiophen- 2-yl-s-but
  • alkenyl refers to a straight chain or a branched chain hydrocarbon group which contains one unsaturated carbon-carbon bonds and does not contain any hetero atoms.
  • Ci-C 6 alkenyl refers to an alkenyl group which has 1-6 carbon atom(s).
  • Ci-C 6 alkenyl examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 3-propenyl, 2-methyl-prop-l-en-l-yl, 2-methyl-prop-l-en-3-yl, but- 1-en-l-yl, but-l-en-2-yl, but-l-en-3-yl, but-2-en-l-yl, but-2-en-2-yl, pent-1-en-l-yl, pent-l-en-2-yl, pent-l-en-3-yl, pent-l-en-4-yl, pent-l-en-5-yl, pent-2-en-l-yl, pent- 2-en-2-yl, pent-2-en-3-yl, pent-2-en-4-yl, pent-2-en-5-yl, 2-methyl-but-l-en-l-yl, 2-methyl-but- l-en-2-yl, 2-
  • alkynyl refers to a straight chain or a branched chain hydrocarbon group which contains one unsaturated carbon-carbon bonds and does not contain any hetero atoms.
  • Ci-C 6 alkynyl refers to an alkynyl group which has 1-6 carbon atom(s).
  • Ci-C 6 alkynyl examples include, but are not limited to, ethinyl, 1-propinyl, 2-propinyl, 3-propinyl, 2-methyl-prop-l-in-l-yl, 2-methyl-prop-l-in-3-yl, but- 1 -in- 1-yl, but-l-in-2-yl, but-l-in-3-yl, but-2-in-l-yl, but-2-in-2-yl, pent- 1 -in- 1-yl, pent- l-in-2-yl, pent-l-in-3-yl, pent-l-in-4-yl, pent-l-in-5-yl, pent-2-in-l-yl, pent-2-in-2-yl, pent-2-in-3-yl, pent-2-in-4-yl, pent-2-in-5-yl, 2-methyl-but-l-in-l-yl, 2-methyl-but- 1 -in
  • alkoxy refers to a group represented by -OR, wherein R is alkyl.
  • Ci-C 6 alkoxy refers to an alkoxy group which has 1-6 carbon atom(s).
  • Ci-C 4 alkoxy refers to an alkoxy group which has 1-4 carbon atom(s).
  • Ci-C 6 alkoxy examples include, but are not limited to, methoxy, ethoxy, 1-propyloxy, 2-propyloxy, 2-methyl-l-propyloxy, 2-methyl-2-propyloxy, and 1-butyloxy, and 2- butyloxy.
  • Ci-C 6 alkylcarbonyl refers to a carbonyl group bound to the Ci-C 6 alkyl.
  • Ci-C 4 alkylcarbonyl refers to a carbonyl group bound to the Ci-C 4 alkyl.
  • Ci-C 6 alkylcarbonyl examples include, but are not limited to, methylcarbonyl, ethylcarbonyl, 1-propylcarbonyl, 2-propylcarbonyl, n-butylcarbonyl, s-butylcarbonyl, t-butylcarbonyl, and 2-ethylbutylcarbonyl.
  • cycloalkyl refers to a saturated carbohydrate ring system.
  • C 3 -C 8 cycloalkyl refers to 3-8 membered cycloalkyl.
  • C 3 -C 8 cycloalkyl examples include, but are not limited to, cyclopropyl, cy- clobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, and cyclooctanyl.
  • amino refers to a group represented by -NH 2 whose hydrogens are optionally substituted by a substituent.
  • Ci-C 6 alkylamino refers to an amino group bound to the Ci -C 6 alkyl.
  • Ci-C 6 alkylamino examples include, but are not limited to, methylamino, ethylamino, 1-propylcarbonylamino, 2-propylamino, n-butylamino, s-butylamino, t- butylamino, and 2-ethylbutylamino.
  • Ci-C 6 alkylcarbonylamino refers to an amino group bound to the Ci-C 6 alkylcarbonyl.
  • Ci-C 4 alkylcarbonylamino refers to an amino group bound to the Ci-C 4 alkylcarbonyl.
  • Ci-C 6 alkylcarbonylamino examples include, but are not limited to, methylcar- bonylamino, ethylcarbonylamino, 1-propylcarbonylamino, 2-propylcarbonylamino, n- butylcarbonylamino, s-butylcarbonylamino, t-butylcarbonylamino, and 2-ethylbutylcarbonylamino.
  • C 3 -C 8 cycloalkylamino refers to an amino group bound to the C 3 -C 8 cycloalkyl.
  • C 3 -C 8 cycloalkyl amino examples include, but are not limited to, cyclo- propylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, cyclohep- tanylamino, and cyclooctanyl amino.
  • sulfonyl is a group represented by -SO 2 -.
  • Ci-C 6 alkylsulfonyl refers to a sulfonyl group bound to the Ci-C 6 alkyl.
  • Ci-C 4 alkylsulfonyl refers to a sulfonyl group bound to the Ci-C 4 alkyl.
  • Ci-C 6 alkylsulfonyl examples include, but are not limited to, methylsulfonyl, ethylsulfonyl, 1-propylsulfonyl, 2-propylsulfonyl, n-butylsulfonyl, s-butylsulfonyl, t- butylsulfonyl, and 2-ethylbutylsulfonyl.
  • Ci-C 6 alkylsulfonylamino refers to an amino group bound to the "Ci-C 6 alkylsulfonyl.
  • Ci-C 4 alkylsulfonylamino refers to an amino group bound to the "Ci-C 4 alkylsulfonyl.
  • Ci-C 6 alkylsulfonylamino examples include, but are not limited to, methylsul- fonylamino, ethylsulfonylamino, 1-propylsulfonylamino, 2-propylsulfonylamino, n- butylsulfonylamino, s-butylsulfonylamino, t-butylsulfonylamino, and 2-ethylbutylsulfonylamino.
  • a saturated heterocyclic group refers to a saturated heterocyclic group having one or more than one hetero atom in the ring system.
  • 3-8 membered saturated heterocyclic group refers to a saturated heterocyclic group whose ring consists of 3-8 atoms.
  • 3-8 membered saturated heterocyclic group examples include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, piperidinyl, azepanyl, and morpholinyl.
  • a salt is defined as the product formed from the neutralization reaction of acids and bases. Salts are ionic compounds composed of cations (positively charged ions) and anions (negative ions) so that the product is electrically neutral. These component ions can be inorganic as well as organic.
  • Hydrate is a term used in inorganic chemistry and organic chemistry to indicate that a substance contains water.
  • Solvate refers to a molecule in a solution complexed by solvent molecules.
  • Isomers are compounds with the same molecular formula but different structural formulae. More specifically, isomer includes geometric isomer, optical isomer, stereoisomer, tautomer of the compound, and mixtures thereof.
  • the present invention provides a compound represented by formula (I): [Chem.2]
  • X is phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, cyclopentyl, phenylCi-C 6 alkyl, thiophen-2-ylCi-C 6 alkyl, furan-2-ylCi-C 6 alkyl, cyclopropylCi-C 6 alkyl, or cy- clopentylCi-C 6 alkyl; the phenyl, thiophen-2-yl, furan-2-yl, cyclopropyl, cyclopentyl, phenylQ -C 6 alkyl, thiophen-2-ylCi-C 6 alkyl, furan-2-ylCi-C 6 alkyl, cyclopropylCi-C 6 alkyl, or cy- clopentylCi-C 6 alkyl are optionally substituted by 1-3 substituent(s) each independently selected from group A;
  • L is -NH- or single bond
  • M is selected C 3 -C 8 cycloalkyl or 3-8 membered saturated heterocyclic group; the C 3 -C 8 cycloalkyl, and 3-8 membered saturated heterocyclic group are optionally substituted by 1-3 substituent(s) each independently selected from group A; wherein group A consists of hydroxyl, oxo, nitro, cyano, amino, Ci-C 6 alky lamino, C 3 -
  • Preferred compounds include those selected from the group consisting of: Example Nos. 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, and 72 listed in Table 1 below; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the forgoing compounds.
  • the compound of formula (I) of the present invention may be in the form of a pharmaceutically acceptable salt derived from an inorganic or organic acid, and repre- sentative examples of the pharmaceutically acceptable salt derived from an inorganic or organic acid include salts obtained by adding an inorganic acid such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfonic acid, or organic carboxylic acids such as acetic acid, trifluoroacetic acid, citric acid, formic acid, maleic acid, oxalic acid, succinic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, ascorbic acid or malic acid, methanesulfonic acid, or para toluenesulfonic acid, which do not limit its scope, to the compound of formula (I).
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfonic acid
  • organic carboxylic acids such as acetic acid, trifluoroace
  • Such acids may be prepared by the conventional processes, and other acids, which themselves are not pharmaceutically acceptable, including oxalic acid may be employed in the preparation of the bases.
  • the compound of formula (I) of the present invention may also be in the form of a pharmaceutically acceptable salt derived from an inorganic or organic base include salts obtained by adding an inorganic or organic base.
  • alkalis including sodium hydroxide or potassium hydroxide, or alkaline earth metal hydroxides including calcium hydroxide, magnesium hydroxide, aluminum hydroxide or ammonium hydroxide may be used for the preparation of inorganic salt of the compound.
  • organic bases including triethylamine or diisopropylethylamine may also be used for the preparation of organic salt of the compound.
  • the preferred inventive compound of formula (I-II) and (I-III) may be prepared as in Scheme (I).
  • p-TSA is p-toluenesulfonic acid
  • HATU is
  • amidine B is reacted with the requisite nitrile in the presence of p-toluenesulfonic acid to afford amidine B.
  • Amidine B is chlorinated with sodium hypochlorite and cyclized using sodium bicarbonate to form benzimidazole C.
  • Intermediate C is saponified with sodium hydroxide to afford methoxy acid D which is reacted with various amines in the presence of HATU to afford amides F.
  • Amides F are treated with boron tribromide to afford compounds of formula (I).
  • Intermediate C is treated with boron tribromide to afford hydroxy acid E which is reacted with various amines using EDC and HOBt to afford compounds of formula (I).
  • Scheme (II) [Chem.4]
  • a salt, hydrate, solvate and isomer of the inventive compound of formula (I) may be prepared by employing any of the known methods.
  • the inventive compound of formula (I), a salt, hydrate, solvate or isomer thereof may be used for the treatment of GSK-3beta dependent diseases such as Alzheimer disease, mania, depression, migraine and type 2 diabetes,, by way of inhibiting GSK-3beta activity, the inventive compound having an IC 50 value (micro M), generally in the range of 0.0001 to 100, for example 0.001 to 50, preferably 0.001 to 10, more preferably 0.001 to 5.
  • the present invention includes a pharmaceutical composition which contains a therapeutically effective amount of the compound of formula (I), a salt, hydrate, solvate or isomer thereof as an active ingredient and a pharmaceutically acceptable carrier; therefore, the pharmaceutical composition of the present invention exerts superior preventive and treating effects on GSK-3beta dependent diseases.
  • a pharmaceutical formulation may be prepared in accordance with any of the conventional procedures.
  • the active ingredient is preferably admixed or diluted with a carrier, or enclosed within a carrier, sachet or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid or liquid material acting as a vehicle, excipient or medium for the active ingredient.
  • the formulations may be in the form of a tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft and hard gelatin capsule, sterile injectable solution, sterile packaged powder and the like.
  • Suitable carriers, excipients, and diluents are lactose, dextrose, sucrose, sorbitol, mannitol, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, and mineral oil.
  • the formulations may additionally include fillers, antiemulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a mammal by employing any of the procedures well known in the art.
  • the pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction.
  • the present composition may contain other pharmaceutical active ingredients so long as they do not inhibit the in vivo function of the compound of the present invention.
  • the composition may further contain chemotherapeutic agents conventionally used for treating Alzheimer disease, mania, depression, migraine or type 2 diabetes .
  • the compounds disclosed here can be used to treat or prevent GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes.
  • the present invention provides methods for treating or preventing GSK- 3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes in a subject by administering to the subject the compounds disclosed here.
  • such compound can be administered to the subject in the form of pharmaceutical composition including the compound of the present invention and pharmaceutically or physiologically acceptable carrier.
  • the pharmaceutical composition of the present invention can be administered via various routes including oral, transdermal, subcutaneous, intravenous and intramuscular introduction for treating GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes in a subject.
  • the present invention also provides the use of the compound of the present invention in manufacturing a pharmaceutical composition for treating GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes .
  • the present invention relates to a use of the compound of the present invention for manufacturing a pharmaceutical composition for treating GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes.
  • the present invention further provides the compound of the present invention for use in the treatment of GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes.
  • the present invention further provides a method or process for manufacturing a pharmaceutical composition for treating GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes , wherein the method or process includes the step for formulating a pharmaceutically or physiologically acceptable carrier with the compound of the present invention as active ingredients.
  • the present invention also provides a method or process for manufacturing a pharmaceutical composition for treating GSK-3beta dependent diseases including Alzheimer disease, mania, depression, migraine and type 2 diabetes, wherein the method or process includes the step for admixing an active ingredient with a pharmaceutically or physiologically acceptable carrier, wherein the active ingredient is the compound of the present invention.
  • the dosage and method of administration vary according to the body- weight, age, and symptoms of the patient; however, one skilled in the art can suitably select them.
  • the dose of a compound of the present invention that regulates its activity depends on the symptoms, the dose is generally about 0.1 mg to about 100 mg per day, preferably about 1.0 mg to about 50 mg per day and more preferably about 1.0 mg to about 20 mg per day, when administered orally to a normal adult human (weight 60 kg).
  • the compound parenterally in the form of an injection to a normal adult human (weight 60 kg), although there are some differences according to the patient, target organ, symptoms and method of administration, it is convenient to intravenously inject a dose of about 0.01 mg to about 30 mg per day, preferably about 0.1 to about 20 mg per day and more preferably about 0.1 to about 10 mg per day.
  • the appropriate dosage amount may be routinely calculated by converting to 60 kg of body- weight. Examples
  • p-Toluenesulfonic acid monohydrate (42 g, 110 mmol) was heated at 120 degrees C and once the solid completely melted, it was placed under high vacuum for 1 h to remove the water. The vacuum was released, aniline (20 g, 55 mmol) and 2-thiophenecarbonitrile (24 g, 110 mmol) were added, and the reaction mixture was heated at 160 degrees C for 4 h. The reaction mixture was cooled to room temperature followed by addition of satd. aq NaHCO 3 (250 mL) and ethyl acetate (250 mL).
  • the desired product was dissolved in trifluo- roacetic acid (2 mL) and stirred for 1 h at room temperature.
  • the reaction mixture was concentrated and eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired products.
  • the desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired products.
  • the desired product was treated with TFA (1-2 mL) for 1 h, concentrated and purified by preparative HPLC (C 18 silica, 10-90% acetonitrile/water with 0.05% TFA).
  • the desired product was obtained as the trifluoroacetic acid salt which was eluted through an ion-exchange column (using methanol and 7 N methanol in ammonia) to obtain the desired products [0079]
  • Example 50 Example 50
  • GSK-3beta activity was measured in the presence or absence of compounds using Z'-LYTE kinase assay (Rodems SM, et al., Assay Drug Dev Technol. 1: 9-19, 2002.) kit with SER/THR 9 peptide (Invitrogen) following the manufacturer's instruction.
  • the Z'-LYTE kinase assay kit employs a fluorescence resonance energy transfer (FRET) between two fluorophores, coumarin and fluorescein, attached to each end of a substrate peptide.
  • FRET fluorescence resonance energy transfer
  • Test compounds were dissolved in DMSO at 12.5 mM and then serially diluted as the DMSO concentration in the assays to be 1%.
  • the serially diluted compounds, 0.04 ng/micro-1 GSK-3beta (Invitrogen) and 2 micro-M SER/THR 9 peptide were reacted in a reaction buffer (50 mM HEPES pH 7.5, 0.01% Brij-35, 10 mM MgCl 2 , 1 mM EGTA, 15 micro-M ATP).
  • a reaction buffer 50 mM HEPES pH 7.5, 0.01% Brij-35, 10 mM MgCl 2 , 1 mM EGTA, 15 micro-M ATP.
  • ATP was omitted from the reaction mixture.
  • SER/THR 9 phosphopeptide was used in place of the SER/THR 9 peptide.
  • CI OD ⁇ coumarin em ission signal of the 100% phosphorylation control
  • Q ⁇ . coumarin emission sign al of the 0% ph osph orylation control
  • FIDD ⁇ fluorescein emission sign al of th e 100% ph osph orylation control
  • Fo ⁇ fluorescein em ission signal of th e ⁇ % phosphorylation control
  • IC 50 values were calculated by nonlinear four parameter fit using SigmaPlot, version 10.0 (Systat Software, Inc.).
  • the present invention provides a novel 7-Hydroxy-benzoimidazole-4-yl-methanone derivative compound having GSK-3beta inhibitory effect.
  • the compounds of the present invention may be used for pharmaceutical composition for inhibiting GSK- 3beta activity in a patient suffering from a GSK-3beta dependent disease.
  • Such pharmaceutical compositions are suitable for treating or preventing Alzheimer disease, mania, depression, migraine and type 2 diabetes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/JP2009/004975 2008-11-20 2009-09-29 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives WO2010058512A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2744012A CA2744012A1 (en) 2008-11-20 2009-09-29 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
CN2009801549899A CN102292083A (zh) 2008-11-20 2009-09-29 包括7-羟基-苯并咪唑-4-基-甲酮衍生物的糖原合酶激酶-3β抑制剂
RU2011124960/04A RU2011124960A (ru) 2008-11-20 2009-09-29 Ингибиторы гликогенсинтаза-киназы 3-бета, содержащие производные 7-гидроксибензоимидазол-4-илметанова
US13/129,361 US20110301146A1 (en) 2008-11-20 2009-09-29 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
JP2011522179A JP2012509249A (ja) 2008-11-20 2009-09-29 ７−ヒドロキシ−ベンゾイミダゾール−４−イル−メタノン誘導体を含むグリコーゲン合成酵素キナーゼ−３ベータ阻害剤
BRPI0920959A BRPI0920959A2 (pt) 2008-11-20 2009-09-29 Inibidores de glicogênio sintase quinase-3 beta contendo derivados de 7-hidróxi-benzoimidazol-4-il-metanona
MX2011005369A MX2011005369A (es) 2008-11-20 2009-09-29 Inhibidores de glicogeno sintasa cinasa-3 beta que contienen derivados de 7-hidroxi-benzoimidazol-4-il-metanona.
EP09827294A EP2358365A4 (en) 2008-11-20 2009-09-29 GLYCOGEN SYNTHASE KINASE 3 BETA HEMMER WITH 7-HYDROXY BENZOIMIDAZOLE-4-YL METHANONE DERIVATIVES
AU2009318719A AU2009318719A1 (en) 2008-11-20 2009-09-29 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
SG2011036282A SG171761A1 (en) 2008-11-20 2009-09-29 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
IL212704A IL212704A0 (en) 2008-11-20 2011-05-05 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
ZA2011/04487A ZA201104487B (en) 2008-11-20 2011-06-17 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11654308P 2008-11-20 2008-11-20
US61/116,543 2008-11-20

Publications (1)

Publication Number Publication Date
WO2010058512A1 true WO2010058512A1 (en) 2010-05-27

Family

ID=42197956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/004975 WO2010058512A1 (en) 2008-11-20 2009-09-29 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives

Country Status (15)

Country Link
US (1) US20110301146A1 (ko)
EP (1) EP2358365A4 (ko)
JP (1) JP2012509249A (ko)
KR (1) KR20110086750A (ko)
CN (1) CN102292083A (ko)
AU (1) AU2009318719A1 (ko)
BR (1) BRPI0920959A2 (ko)
CA (1) CA2744012A1 (ko)
CO (1) CO6361935A2 (ko)
IL (1) IL212704A0 (ko)
MX (1) MX2011005369A (ko)
RU (1) RU2011124960A (ko)
SG (1) SG171761A1 (ko)
WO (1) WO2010058512A1 (ko)
ZA (1) ZA201104487B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0916726A2 (pt) * 2008-07-30 2017-07-04 Oncotherapy Science Inc derivados de benzoimidazol e inibidores de glicogêncio sintase quinase-3 beta contendo os mesmos
CN101619058A (zh) * 2009-01-08 2010-01-06 上海交通大学 一种苯并咪唑-4-酰胺型衍生物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515013A (ja) * 2003-01-23 2006-05-18 クリスタルジェノミクス、インコーポレイテッド グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CN102271514A (zh) * 2008-10-30 2011-12-07 肿瘤疗法科学股份有限公司 7-羟基-苯并咪唑-4-基-甲酮衍生物以及包含其的pbk抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515013A (ja) * 2003-01-23 2006-05-18 クリスタルジェノミクス、インコーポレイテッド グリコーゲン合成酵素キナーゼ３β活性抑制剤、組成物及びその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIN, DONGKYU ET AL.: "Design and synthesis of 7-hydroxy-lH-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 5686 - 5689, XP022249693 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198699B2 (en) 2019-04-02 2021-12-14 Aligos Therapeutics, Inc. Compounds targeting PRMT5

Also Published As

Publication number Publication date
EP2358365A4 (en) 2012-05-30
AU2009318719A1 (en) 2011-06-30
RU2011124960A (ru) 2012-12-27
ZA201104487B (en) 2012-03-28
SG171761A1 (en) 2011-07-28
CN102292083A (zh) 2011-12-21
KR20110086750A (ko) 2011-07-29
EP2358365A1 (en) 2011-08-24
JP2012509249A (ja) 2012-04-19
CO6361935A2 (es) 2012-01-20
BRPI0920959A2 (pt) 2017-07-11
US20110301146A1 (en) 2011-12-08
MX2011005369A (es) 2011-06-20
CA2744012A1 (en) 2010-05-27
IL212704A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
US20110263566A1 (en) 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives and PBK Inhibitors Containing the Same
AU2006241210B2 (en) Fused heterocyclic compounds
AU2008335880B2 (en) Hedgehog pathway antagonists and therapeutic applications thereof
US6518292B1 (en) Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU1345001A (en) 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists
US8835648B2 (en) Hedgehog pathway antagonists and therapeutic applications thereof
CA2732280A1 (en) Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same
EP2155719A1 (en) Azacyclylbenzamide derivatives as histamine-3 antagonists
WO2010058512A1 (en) Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
AU2006291414A1 (en) Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
US6525203B1 (en) Heterocyclic aromatic compounds useful as growth hormone secretagogues
KR101343399B1 (ko) 통증 치료를 위한 카나비노이드 수용체에 대한 리간드로서의 프롤린 유사체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980154989.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09827294

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 212704

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2744012

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 592932

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2011522179

Country of ref document: JP

Ref document number: 11061830

Country of ref document: CO

Ref document number: 12011500978

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/005369

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009318719

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 4208/CHENP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117014051

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011124960

Country of ref document: RU

Ref document number: A201107289

Country of ref document: UA

Ref document number: 2009827294

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009318719

Country of ref document: AU

Date of ref document: 20090929

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13129361

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0920959

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110519